Source comparison
Dosing Structures That Drive Recomposition vs Weight Loss
Dosing determines outcome. The tesamorelin + ipamorelin blend can be structured for three distinct metabolic goals: aggressive fat loss with muscle preservation, moderate recomposition with lean gains, or maintenance recomposition during metabolic plateaus. Th
This comparison does not assign a generated winner or score.
- Dosing determines outcome. The tesamorelin + ipamorelin blend can be structured for three distinct metabolic goals: aggressive fat loss with muscle preservation, moderate recomposition with lean gains, or maintenance recomposition during metabolic plateaus. The difference comes down to dose ratios, total peptide load, and injection frequency.
- Standard recomposition protocols use tesamorelin at 1–2mg daily paired with ipamorelin at 200–300mcg per dose, administered once or twice daily. The 1mg tesamorelin dose approximates half the FDA-approved Egrifta dosing for lipodystrophy, while the ipamorelin range falls within established GH secretagogue research parameters. Timing matters: administering ipamorelin 30–60 minutes before the body's natural nocturnal GH pulse (typically 90–120 minutes after sleep onset) amplifies the endogenous spike without disrupting circadian rhythms. Tesamorelin, with its 26–38 minute half-life, can be dosed in the morning to create a secondary GH pulse during waking hours—this biphasic pattern (morning + evening) mimics the natural pulsatile secretion more closely than single daily dosing.
- Our experience shows the ratio between compounds influences body composition outcomes more than total dose. A 5:1 tesamorelin-to-ipamorelin ratio (e.g., 2mg tesamorelin with 400mcg ipamorelin) skews toward visceral fat mobilization with moderate muscle retention—effective for individuals carrying significant VAT who prioritize fat reduction. A 3:1 ratio (e.g., 1.5mg tesamorelin with 500mcg ipamorelin) balances lipolysis and anabolism more evenly, supporting simultaneous fat loss and lean gains in individuals already at moderate body fat percentages. Adjusting the ratio allows fine-tuning without changing total peptide exposure.
- The critical mistake: treating the blend as a simple fat-loss tool and pairing it with aggressive caloric deficits. GH elevation increases lipolysis, but protein synthesis pathways require adequate substrate—leucine availability, specifically, at the 2.5–3g per-meal threshold required for mTOR activation. Running the blend on insufficient protein intake (below 1.6g/kg daily) wastes the anabolic component entirely. You'll lose fat, but you'll also lose muscle. That's weight loss, not recomposition.